The MDM2 inhibitor AMG 232 causes tumor regression and potentiates the anti-tumor activity of MEK inhibition and DNA-damaging cytotoxic agents in preclinical models of acute myeloid leukemia

被引：3
|
作者：
Canon, Jude R.
Osgood, Tao
Saiki, Anne Y.
Oliner, Jonathan D.
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-3761
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3761
引用
收藏
页数：3
相关论文
共 20 条
  • [1] The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents
    Canon, Jude
    Osgood, Tao
    Olson, Steven H.
    Saiki, Anne Y.
    Robertson, Rebecca
    Yu, Dongyin
    Eksterowicz, John
    Ye, Qiuping
    Jin, Lixia
    Chen, Ada
    Zhou, Jing
    Cordover, David
    kaufman, Stephen
    Kendall, Richard
    Oliner, Jonathan D.
    Coxon, Angela
    Radinsky, Robert
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (03) : 649 - 658
  • [2] ABT-888, an orallyactive poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models
    Donawho, Cherrie K.
    Luo, Yan
    Luo, Yanping
    Penning, Thomas D.
    Bauch, Joy L.
    Bouska, Jennifer J.
    Bontcheva-Diaz, Velitchka D.
    Cox, Bryan F.
    DeWeese, Theodore L.
    Dillehay, Larry E.
    Ferguson, Debra C.
    Ghoreishi-Haack, Nayereh S.
    Grimm, David R.
    Guan, Ran
    Han, Edward K.
    Holley-Shanks, Rhonda R.
    Hristov, Boris
    Idler, Kenneth B.
    Jarvis, Ken
    Johnson, Eric F.
    Kleinberg, Lawrence R.
    Klinghofer, Vered
    Lasko, Loren M.
    Liu, Xuesong
    Marsh, Kennan C.
    McGonigal, Thomas P.
    Meulbroek, Jonathan A.
    Olson, Amanda M.
    Palma, Joann P.
    Rodriguez, Luis E.
    Shi, Yan
    Stavropoulos, Jason A.
    Tsurutani, Alan C.
    Zhu, Gui-Dong
    Rosenberg, Saul H.
    Giranda, Vincent L.
    Frost, David J.
    CLINICAL CANCER RESEARCH, 2007, 13 (09) : 2728 - 2737
  • [3] Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models
    Lehmann, Christian
    Friess, Thomas
    Birzele, Fabian
    Kiialainen, Anna
    Dangl, Markus
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
  • [4] Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models
    Christian Lehmann
    Thomas Friess
    Fabian Birzele
    Anna Kiialainen
    Markus Dangl
    Journal of Hematology & Oncology, 9
  • [5] Combination of MDM2 inhibition with milademetan and MEK inhibition leads to improved anti-tumor activity in cancer models harboring WT TP53
    Tirunagaru, V.
    Singh, K.
    Pei, X.
    Doebele, R. C.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S20 - S21
  • [6] MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models
    Douglas D. Fang
    Qiuqiong Tang
    Yanhui Kong
    Tao Rong
    Qixin Wang
    Na Li
    Xu Fang
    Jiaxing Gu
    Dengkun Xiong
    Yan Yin
    Jing Deng
    Dajun Yang
    Yifan Zhai
    Cell Death Discovery, 7
  • [7] MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models
    Fang, Douglas D.
    Tang, Qiuqiong
    Kong, Yanhui
    Rong, Tao
    Wang, Qixin
    Li, Na
    Fang, Xu
    Gu, Jiaxing
    Xiong, Dengkun
    Yin, Yan
    Deng, Jing
    Yang, Dajun
    Zhai, Yifan
    CELL DEATH DISCOVERY, 2021, 7 (01)
  • [8] A novel MDM2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer
    Tortora, G
    Caputo, R
    Damiano, V
    Bianco, R
    Chen, JD
    Agrawal, S
    Bianco, AR
    Ciardiello, F
    INTERNATIONAL JOURNAL OF CANCER, 2000, 88 (05) : 804 - 809
  • [9] Combined inhibition of MCL1 and BCL-2 with AMG 176 and venetoclax induces anti-tumor effects in primary patient samples and models of acute myeloid leukemia
    Caenepeel, Sean R.
    Osgood, Tao
    Belmontes, Brian
    Sun, Jan
    Cajulis, Elaina
    Wei, Andrew
    Coxon, Angela
    Canon, Jude
    Hughes, Paul
    CANCER RESEARCH, 2018, 78 (13)
  • [10] Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification
    Cornillie, J.
    Wozniak, A.
    Li, H.
    Gebreyohannes, Y. K.
    Wellens, J.
    Hompes, D.
    Debiec-Rychter, M.
    Sciot, R.
    Schoffski, P.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (04): : 546 - 554
12